Abstract
BackgroundThe variation of drug responses and target does among individuals is mostly determined by genes. With the development of pharmacogenetics and pharmacogenomics, the differences in drug response between different races seem to be mainly caused by the genetic diversity of pharmacodynamics and pharmacokinetics genes. Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB). The information of Chinese ethnic minorities such as the Wa ethnic group is scarce. This study aimed to uncover the significantly different loci in the Wa population in Yunnan Province of China from the perspective of pharmacogenomics, to provide a theoretical basis for the future medication guidance, and to ultimately achieve the best treatment in the future.ResultsIn this study, we recruited 200 unrelated healthy Wa adults from the Yunnan province of China, selected 52 VIP variants from the PharmGKB for genotyping. We also compared the genotype frequency and allele distribution of VIP variants between Wa population and the other 26 populations from the 1000 Genomes Project (http://www.1000Genomes.org/). Next, χ2 test was used to determine the significant points between these populations. The study results showed that compared with the other 26 population groups, five variants rs776746 (CYP3A5), rs4291 (ACE), rs3093105 (CYP4F2), rs1051298 (SLC19A1), and rs1065852 (CYP2D6) had higher frequencies in the Wa population. The genotype frequencies rs4291-TA, rs3093105-CA, rs1051298-AG and rs1065852-GA were higher than those of the other populations, and the allele distributions of rs4291-T and rs3093105-C were significantly different. Additionally, the difference between the Wa ethnic group and East Asian populations, such as CDX, CHB, and CHS, was the smallest.ConclusionsOur research results show that there is a significant difference in the distribution of VIP variants between the Wa ethnic group and the other 26 populations. The study results will have an effect on supplementing the pharmacogenomics information for the Wa population and providing a theoretical basis for individualised medication for the Wa population.
Highlights
The variation of drug responses and target does among individuals is mostly determined by genes
We used the chi-square test to study the frequency distribution of 52 loci and compared the Wa ethnic group with the other 26 different populations from the 1000 Genomes Project (CDX, Han Chinese in Beijing (CHB), Chinese South (CHS), Japanese in Tokyo (JPT), Kinh in Ho Chi Minh City (KHV), African Caribbean in Barbados (ACB), Ancestry in Southwest US (ASW), Esan in Nigeria (ESN), Gambian in Western Divisions (GWD), LWK, Mende in Sierra Leone (MSL),YRI, CLM, MXL, Peruvian in Lima (PEL), Puerto Rican in Puerto Rico (PUR), CEU, FIN, British in England and Scotland (GBR), Iberian populations in Spain (IBS), Toscani in Italy (TSI), Bengali in Bangladesh (BEB), GIH, in the UK (ITU), Punjabi in Lahore (PJL) and Sri Lankan Tamil in the UK (STU))
We found that the significant differences between KHV, JPT, Chinese Dai in Xishuangbanna (CDX), LWK and Wa people were in rs3093105 and rs1065852
Summary
The variation of drug responses and target does among individuals is mostly determined by genes. With the development of pharmacogenetics and pharmacogenomics, the differences in drug response between different races seem to be mainly caused by the genetic diversity of pharmacodynamics and pharmacokinetics genes. Increasing evidence shows that genetic differences between individuals are an important factor to ADR [1]. Pharmacogenomics is a discipline that studies how genetic factors affect the responses of individuals to drug therapy [2] and transforms the drug responses of individuals into a molecular diagnosis. It can be used for individualised drug therapy [3]. It is necessary to integrate genomic data into the benefit and risk assessment of daily treatment so that individualised treatment has a certain possibility to vary from person to person [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
